17 results about "Premature birth" patented technology

The invention discloses a vagina microbial marker combination, which is characterized in that the vagina microbial marker combination is composed of Lactobacillus indices and Bifidobacterium dentium, and the vagina microbial marker combination is used for assisting in evaluating the premature delivery risk of a pregnant woman suffering from cervical insufficiency and subjected to transvaginal cervical cerclage. Therefore, the premature delivery can be predicted based on the vagina microbial marker combination, so that decisions and help are provided for clinicians to judge whether the pregnant woman is premature delivery or not.

This invention discloses a resveratrol derivative or its pharmaceutical salt, with the following general structural formula:; This invention also discloses the application of the resveratrol derivative or its pharmaceutical salt in the preparation of drugs for preventing and treating premature birth.

This invention belongs to the field of microbial technology, specifically disclosing a probiotic composition and its application. The probiotic composition provided by this invention includes at least two of the following: prebiotics, vitamin K, and zinc, as well as *Bifidobacterium longum* subsp. infantis i18. The probiotic composition provided by this invention can not only effectively promote the growth and development of premature mice, but also optimize the intestinal flora structure and promote intestinal development in premature infants by reducing the abundance of harmful bacteria and increasing the relative abundance of beneficial bacteria; simultaneously, it can downregulate the levels of pro-inflammatory factors TNF-α and IL-6, reducing intestinal inflammation and lowering the risk of necrotizing enterocolitis in premature infants. This invention can be applied to the preparation of products that improve the intestinal flora of premature infants, promote their growth, or prevent intestinal inflammation.

The invention belongs to the technical field of obstetrics and gynecology disease prediction, and particularly relates to a premature fetal membrane premature rupture prediction marker based on maternal circulation exosome microRNA and an application kit. According to the invention, placentas, fetal membranes and plasma exosomes of pregnant women with full-term birth and premature birth premature rupture of fetal membranes are collected for sequencing, the fetal membrane-derived exosome hsa-miR-145-3p which can be detected in the plasma exosomes is screened out in combination with a verification set, and the cell source and the premature birth promoting effect of the fetal membrane-derived exosome hsa-miR-145-3p are respectively clarified at a cell level and an animal level; and finally, by detecting the level of the plasma exosome hsa-miR-145-3p of the pregnant 12 (+ 1)-17 (+ 6) perimaternal body, the efficiency (AUC = 0.833) of the exosome in predicting the occurrence of premature rupture of fetal membranes in premature delivery is illustrated. According to the method, the high-risk crowd of the pPROM can be predicted through a noninvasive method in the early and middle stages of pregnancy, and the method has guiding significance for subsequent prevention and intervention of the high-risk crowd.

The invention relates to a flora prediction model for detecting premature delivery risk and a kit and application thereof. Through early-stage mNGS data collection and analysis, premature related strains are obtained, and through a large number of experimental screening and optimization, a set of optimal primer probe group is finally determined. The invention relates to a premature delivery risk calculation method, which comprises the following steps of: selecting 12 floras, namely lactobacillus crispatus, lactobacillus gasseri, lactobacillus inertus, lactobacillus jensenii, escherichia coli, enterococcus faecalis, enterobacter aerogenes, group B hemolytic streptococcus, ureaplasma parvum, chlamydia trachomatis, diplococcus gonorrhoeae and gardnerella vaginalis, and establishing a fluorescent quantitative PCR (Polymerase Chain Reaction) method and a premature delivery risk calculation model aiming at the detection of the 12 floras. Compared with an existing detection method, the method is simple, convenient, rapid, high in sensitivity and high in specificity, the false positive and false negative risk is reduced, and the purpose of batch detection is achieved. Clinically, the change of microbial flora in the reproductive system of a pregnant woman can be rapidly detected, corresponding treatment measures are taken, the risk of PTB occurrence is reduced, and the kit has a good application prospect.

The application discloses albendazole and ivermectin premix and a preparation method thereof. The premix comprises albendazole 8-15%, ivermectin 0.2-0.4%, double-layer inclusion carrier 20-30% and various auxiliary materials in percentage by mass. The application adopts the double-layer inclusion carrier formed by inner layer hydroxypropyl-beta-cyclodextrin and outer layer hydroxypropyl methylcellulose phthalate and povidone K30 to form an enteric barrier. The preparation method comprises the steps of inner layer inclusion, outer layer dispersion, mixing and granulation. The relative bioavailability of the premix reaches 203%-221%, the pig ascarid drive rate is 98.7%-99.5%, the scabies mite negative conversion rate is 98%-100%, the diarrhea incidence is only 2%-3%, the premix is safe for pregnant sow groups, and no adverse reactions such as abortion, premature birth and loss of appetite occur in all test pigs during the test period. The problems of uneven mixing, low bioavailability and large side effects of traditional preparations are solved, and the premix is suitable for livestock and poultry parasite prevention and treatment.

The bed pan comprises a frame body, the frame body is in a transverse V-shaped folded plate shape, a through-hole-shaped defecation hole is formed in a top plate of the frame body, and a supporting plate is arranged on the side face of the frame body; the supporting plate is triangular, and the two side edges of the supporting plate are connected with the top plate and the bottom plate of the frame body respectively. A cleaning bag is further included. The clean bag is in a soft bag shape and is arranged below the defecation hole, and the upper end of the clean bag is open and larger than the defecation hole; the cleaning bag is detachably connected with the bottom face of the top plate through a connecting structure so that the cleaning bag can be aligned with the defecation hole. According to the utility model, the fetus protection pregnant woman can complete defecation on the premise that the hip height lying position is not changed, so that the living requirements of a patient are effectively met, and the premature delivery risk is reduced without changing the body position. Meanwhile, by using the disposable and replaceable clean bag, the hidden danger of excrement leakage is eliminated, the probability of cross contamination is reduced, and favorable conditions are created for smooth treatment.

The present application relates to the field of medical data analysis, and more particularly to a method for dynamically predicting the risk of pre-eclampsia premature birth based on monitoring indicators during pregnancy, which comprises: obtaining an individual measured time series set and a basic time weighted average feature; obtaining a recent transient decompensation momentum factor by performing recent deterioration dynamics analysis on monitoring data near the current evaluation time; obtaining a steady-state fracture and barrier breakdown factor by jointly evaluating the evolution trend and fluctuation potential of the historical monitoring sequence; obtaining a reconstructed fusion feature vector by fusing and reconstructing the basic time weighted average feature and the steady-state fracture and barrier breakdown factor; and obtaining a dynamic prediction result of the risk of premature birth by inputting the reconstructed fusion feature vector into a Cox proportional hazards model for risk prediction, thereby solving the problem that the existing prediction method based on time weighted average and linear feature fusion cannot effectively identify recent decompensation deterioration signals and maternal-fetal state deviation risks.

The application provides application of a YTHDC1 inhibitor in preparation of a medicine for preventing and treating premature birth, and the medicine takes YTHDC1 gene as a target for placental trophoblasts. The application is based on the fact that the expression level of human YTHDC1 gene in premature placental tissue is significantly higher than that in full-term placenta, a stable overexpression cell strain is constructed aiming at human YTHDC1 gene, and specific siRNA is designed to specifically increase or reduce YTHDC1 expression in human placental trophoblasts, which can correspondingly promote or inhibit the proliferation, apoptosis, migration and invasion ability of the cells. Meanwhile, by injecting in vivo biological preparations interfering with the expression of YTHDC1 gene in an animal model, the expression of YTHDC1 at the placental site can be reduced, the delivery time is prolonged, and the purpose of delaying the occurrence of premature birth is achieved. The application provides a possibility for the development of a clinical premature birth treatment medicine based on YTHDC1 gene, and has great application value and prospect.

Systems, devices, and methods are provided for controlling, supporting, and / or elongating the cervix in order to treat pregnancy complications and / or delay the onset of labor, thereby prolonging the gestation period of the fetus and thereby preventing premature birth and delivery of the fetus. The cervical control system may include a main body configured for placement in the vagina. The main body has an internal passage configured for receiving the cervix therein, and an inflatable and / or expandable internal cuff extending from a portion of the internal passage. The internal cuff may be expandable inward toward the cervix, or inward toward the uterus, or both inward and inward, so that the internal cuff may engage with or grasp the cervix, thereby holding the cervical control system in place while compressing and closing the cervix, elongating the cervix, and / or adjusting the angle of orientation of the cervix.

The present invention relates to treating, preventing or reducing a respiratory complication in a premature infant subject. In particular, the present invention provides Lactobacillus reuteri for use in treating or preventing or reducing a respiratory complication in a premature infant subject. The present invention also provides methods of treating or preventing or reducing a respiratory complication in a premature infant subject, comprising administering to said subject an effective amount of Lactobacillus reuteri. The present invention also relates to reducing risk of mortality in a premature infant subject. The present invention provides Lactobacillus reuteri for use in reducing risk of mortality in a premature infant subject. The present invention also provides methods of reducing risk of mortality in a premature infant subject, comprising administering to said subject an effective amount of Lactobacillus reuteri.

A method for shortening the duration of mechanical ventilation in premature infants at risk of developing bronchopulmonary dysplasia (BPD) includes administering an effective amount of recombinant human surfactant protein D (rhSP-D) to the infant. In a further embodiment, a method for shortening the length of hospital stay in premature infants at risk of developing BPD includes administering an effective amount of rhSP-D to the infant. In a specific embodiment, a method for reducing the probability that premature infants at risk of developing BPD will develop one or more secondary complications due to preterm birth includes administering an effective amount of recombinant human surfactant protein D (rhSP-D) to the infant. Pharmaceutical compositions for use in the described methods and uses of the pharmaceutical compositions are also described.

The invention discloses a premature delivery risk assessment method and system based on multi-modal physiological signals. The method comprises the following steps: S1, acquiring uterus electromyographic signals of a pregnant woman, identifying explosive waves, and obtaining a uterus electromyographic characteristic matrix X1; s2, collecting basic information BMI, age AGE, premature delivery history and pregnancy complications of the pregnant woman to obtain a classification feature matrix X2; s3, acquiring an iconography identification length sequence VL of the cervix uteri of the pregnant woman to obtain an image feature matrix X3; s4, performing model training on the X1, the X2 and the X3 to obtain a model M1, a model M2 and a model M3; s5, training the models M1, M2 and M3 by adopting adaptive weighted fusion to obtain weights W1, W2 and W3 of the models M1, M2 and M3 in the premature delivery prediction task; and S6, sorting the weights calculated in the step S5 from high to low, splicing the weights to obtain fused feature vectors, and retraining the fused feature vectors to obtain a final premature delivery risk assessment model. According to the method, early prediction of the premature delivery risk is realized, the risk probability and the confidence interval are output, and objective decision support is provided for clinicians.

This invention belongs to the field of pharmaceutical technology and relates to a novel medical use of caffeine for premature infants, specifically its application in improving jaundice in premature infants. This invention analyzes clinical data from premature infants, constructs a mouse model of jaundice, and conducts in vivo imaging and gene knockout verification experiments in premature mice. It was found that clinical caffeine treatment can effectively reduce serum bilirubin levels in premature infants; in jaundice mice and premature mouse models, caffeine intervention significantly reduces brain tissue and serum bilirubin concentrations; gene knockout mouse experiments confirmed that caffeine enhances hepatic bilirubin uptake by upregulating OATP1A / 1B. The caffeine in this invention shows a significant effect in improving neonatal jaundice. Furthermore, caffeine is a commonly used medication for premature infants, is easy to use, and is readily accepted by medical staff and families, making it suitable for relieving apnea combined with jaundice symptoms in premature infants.

The present application relates to the technical field of molecular biology, and particularly relates to a primer group and a kit for detecting multiple pathogens through multiplex amplification targeted sequencing; the primer group comprises primers with nucleotide sequences shown in SQE ID NO. 1-SQE ID NO. 442, which are designed according to highly conserved and specific genomic regions of each pathogen, so as to ensure the specificity of amplification and the coverage of different variant strains; the primer group is suitable for prenatal TORCH screening, detection of pathogenic microorganisms of pregnant women with premature birth indications, screening of pathogenic microorganisms of suspected intrauterine infections, and detection of pathogenic microorganisms of unexplained abortion, and can simultaneously detect pathogenic microorganisms such as viruses, bacteria, fungi and parasites, and has high sensitivity and specificity.